Idexx Laboratories (IDXX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$535.38+1.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Intact: The reason to own it still holds.
Idexx grows revenue about 10% a year, led by 14% growth in CAG Diagnostics recurring revenue. Profit margins stay strong near 32%. The company raised its 2026 revenue guidance to about $4.7 billion and EPS outlook to $14.45. Free cash flow remains positive and supports ongoing investments.
Recurring revenue growth could slow if vet visits plateau. Rising costs may pressure profit margins below 31%. Leadership changes and recent soft guidance raise execution risks. If revenue growth falls below 7%, the business model may be weaker than expected.
The stock price is about 28% above our valuation level. Analysts expect roughly 10% revenue growth. Our view is that current estimates are reasonable but leave limited upside given execution risks and valuation.
Breaks if: YoY growth falls below 7% in FY26
Breaks if: EPS falls below $13.00 in FY26
Breaks if: operating margin falls below 30% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
IDXX represents a durable compounder with a focus on consistent revenue and earnings growth. The current thesis state is intact, supported by recent financial performance that remains strong relative to its industry.
The market seems to be pricing in a durable premium, reflecting a 26% expectations gap compared to peers. However, the valuation is considered unjustified given the low fragility tier, indicating that the current price may not fully reflect the company's execution quality.
Fundamentals are likely to remain stable as management continues to raise revenue and earnings guidance. Recent results have shown strong growth in recurring revenue, particularly in CAG Diagnostics, although there is a moderate risk of missing future earnings expectations.
The long-term thesis hinges on management's ability to maintain guidance increases and the overall health of the healthcare sector. Key factors include the performance of sector bellwethers and potential shifts in economic conditions that could impact cyclical names like IDXX.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company increased its 2026 revenue guidance. It is also expanding CAG Diagnostics recurring revenue. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue growth falls below 7% in FY26
Overall, IDXX appears well-positioned for the next few years, but it must navigate sector dynamics and execution risks. Not investment advice.